Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma

Malignant pleural mesothelioma (MPM) remains a devastating disease with an increasing worldwide incidence. Prognosis is poor; median overall survival is only 9-18 months. Few patients are suitable for surgery and the mainstay of therapy remains systemic cytotoxic chemotherapy. Combination cisplatin/pemetrexed is the standard of care first line regimen, offering survival benefit of a few months. Patients invariably progress, and while there is currently no established second line regimen, single agent vinorelbine is used on the basis of activity in small trials.

Source: Lung Cancer - December 5, 2018 Category: Cancer & Oncology Authors: Neelam Kumar, Doraid Alrifai, Krishna K Kolluri, Elizabeth K Sage, Yuki Ishii, Naomi Guppy, Elaine Borg, Mary Falzon, Matthew Nankivell, Andrew Nicholson, Sam M Janes Source Type: research